Target type: biologicalprocess
Any process that decreases or stops the frequency, rate or extent of the regulated release of growth hormone from a cell. [GOC:dph]
Negative regulation of growth hormone secretion is a complex process that involves multiple regulatory pathways and feedback loops. It ensures that growth hormone (GH) production and release are tightly controlled, preventing excessive growth and maintaining overall homeostasis.
**Hypothalamic-Pituitary Axis:**
The primary regulatory mechanism for GH secretion involves the hypothalamic-pituitary axis. The hypothalamus, located in the brain, produces two key hormones that regulate GH release from the pituitary gland:
- **Growth hormone-releasing hormone (GHRH):** Stimulates GH synthesis and release from the anterior pituitary gland.
- **Somatostatin:** Inhibits GH release from the anterior pituitary gland.
**Feedback Mechanisms:**
- **Negative feedback by GH:** GH itself acts as a negative regulator, inhibiting the release of GHRH from the hypothalamus and suppressing its own production by the pituitary gland. This feedback loop helps maintain appropriate GH levels.
- **Negative feedback by insulin-like growth factor 1 (IGF-1):** IGF-1, a hormone produced in response to GH action, also exerts negative feedback. IGF-1 directly inhibits GH release from the pituitary and indirectly suppresses GHRH secretion from the hypothalamus.
**Other Regulatory Factors:**
- **Stress:** Psychological and physical stress can suppress GH secretion.
- **Nutritional status:** Malnutrition or fasting can decrease GH production.
- **Sleep:** Deep sleep stages promote GH release, while sleep deprivation can reduce it.
- **Age:** GH secretion naturally declines with age.
- **Hormones:** Other hormones, including thyroid hormones, cortisol, and sex hormones, can influence GH regulation.
**Molecular Mechanisms:**
The negative regulation of GH secretion involves various molecular mechanisms, including:
- **G protein-coupled receptor signaling:** GHRH and somatostatin bind to their respective G protein-coupled receptors on pituitary cells, triggering intracellular signaling cascades that regulate GH production and release.
- **Gene expression regulation:** Transcription factors and signaling pathways influence the expression of genes involved in GH synthesis and release.
- **Post-translational modifications:** GH undergoes post-translational modifications, such as phosphorylation, that can affect its stability and secretion.
**Consequences of Dysregulation:**
Disruption of negative regulation of GH secretion can lead to various clinical conditions, including:
- **Gigantism:** Excessive GH production during childhood can result in abnormally tall stature.
- **Acromegaly:** Excessive GH production in adulthood can cause thickening of bones and soft tissues.
- **Dwarfism:** Insufficient GH production during childhood can lead to short stature.
**Conclusion:**
Negative regulation of growth hormone secretion is a complex and tightly controlled process that ensures appropriate GH levels throughout life. It involves multiple regulatory pathways and feedback loops, ensuring proper growth and overall homeostasis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Tyrosine-protein phosphatase non-receptor type 11 | A tyrosine-protein phosphatase non-receptor type 11 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q06124] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
glycyrrhetinic acid | cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid | immunomodulator; plant metabolite | |
oxanilic acid | oxanilic acid: RN given refers to parent cpd; structure | ||
oleanolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | plant metabolite | |
phosphotyrosine | O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group. Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis. | L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine | Escherichia coli metabolite; immunogen |
vanadates | vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms. Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects. | trivalent inorganic anion; vanadium oxoanion | EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor |
4-methylumbelliferyl phosphate | |||
maslinic acid | (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria | dihydroxy monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite |
nsc-87877 | NSC-87877: potent Shp2 (nonreceptor protein tyrosine phosphatase) inhibitor; structure in first source | ||
tingenone | tingenone: quinonoid triterpene isolated from Euonymus tingens | ||
geniposide | terpene glycoside | ||
tanshinone | tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent | abietane diterpenoid | anticoronaviral agent |
celastrol | monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite | |
cryptotanshinone | cryptotanshinone: from Salvia miltiorrhiza | abietane diterpenoid | anticoronaviral agent |
tanshinone ii a | tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source | abietane diterpenoid | |
nsc-89199 | estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine. | carbamate ester; organochlorine compound; steroid phosphate | |
estramustine | estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid. Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. | 17beta-hydroxy steroid; carbamate ester; organochlorine compound | alkylating agent; antineoplastic agent; radiation protective agent |
genipin | iridoid monoterpenoid | anti-inflammatory agent; antioxidant; apoptosis inhibitor; cross-linking reagent; hepatotoxic agent; uncoupling protein inhibitor | |
cefsulodin | cefsulodin : A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic. Cefsulodin: A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients. | cephalosporin; organosulfonic acid; primary carboxamide | antibacterial drug |
nsc 117199 | |||
illudalic acid | illudalic acid: isolated from Clitocybe illudens; structure in first source | ||
2-amino-6-chloropurine | 6-chloroguanine : An organochlorine compound that is 7H-purin-2-amine substituted by a chloro group at position 6. 6-chloroguanine: an antimalarial that inhibits hypoxanthine-guanine-xanthine phosphoribosyltransferase; structure in first source | 2-aminopurines; organochlorine compound | |
4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid | |||
Dihydrotanshinone I | dihydrotanshinone I: extracted from Radix Salviae | abietane diterpenoid | anticoronaviral agent |
3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid | 3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid: an SHP2 inhibitor; structure in first source |